The randomized phase II GRIFFIN study showing that the addition of Darzalex (daratumumab) to bortezomib, lenalidomide, and dexamethasone induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation compared with VRd alone.
Last summer, Anirban Maitra, a pathologist specializing in pancreatic cancer, joined the NYU Langone Health Laura and Isaac Perlmutter Cancer Center to co-lead its Gastrointestinal Cancer Center.
